Project Grant HT94252310610
Award Date
9/30/23
Completion Date
9/29/24
Dollars Obligated
$178K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
The Department of the Army Medical Command awarded a $884,997 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program. The three-year grant will fund research to intervene in the TP53 pathway phosphatome in pediatric high-grade gliomas. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research that investigates medical solutions...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $708,100 Project Grant to the Dana-Farber Cancer Institute, Inc. (Dfci) to conduct research on "Overcoming Rebound Growth of Pediatric Low-Grade Glioas Following MAPK Pathway Inhibition." The grant, which runs from July 1, 2024 to June 30, 2026, will support Dfci's efforts to better understand the mechanisms driving recurrence of pediatric low-grade glioma brain tumors after...
The Department of the Army Medical Command awarded a $1,750,524 project grant to Dana-Farber Cancer Institute, Inc. for research on treatment options for metastatic osteosarcoma. The grant was awarded on August 1, 2022 under the Military Medical Research and Development program (CFDA 12.420) and will support research through July 31, 2025. The Military Medical Research and Development program aims to transform health care for service members and the public through innovative biomedical research....
The Defense Health Agency awarded a $1,290,499 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "ENHANCING THE ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS IN OVARIAN CANCER," is focused on advancing research to improve the efficacy of natural killer cell-based therapies for ovarian cancer. DFCI, a leading nonprofit cancer research center, will leverage its expertise in areas such...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This federal Project Grant award from the Defense Health Agency provides $1,591,200.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research on the measurement and impact of body composition using CT imaging in patients with germ cell tumors undergoing chemotherapy. The research falls under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for service members and the public. DFCI, a non-profit hospital...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...